..Although vaccination has been proved to be a safe, efficacious, and cost-effective intervention, immunisation rates remain suboptimal in many European countries, resulting in poor control of many vaccine-preventable diseases...

Vaccine development for an imminent pandemic: why we should worry, what we must do

David S FedsonHum Vaccin 2:38-42. 2006

..Vaccination for an imminent pandemic requires a global perspective not only for vaccine development but also for vaccine production and distribution...

Confronting an influenza pandemic with inexpensive generic agents: can it be done?

David S FedsonLancet Infect Dis 8:571-6. 2008

....

NEW technologies for meeting the global demand for pandemic influenza vaccines

David S FedsonBiologicals 36:346-9. 2008

..These technologies could help meet the global demand for pandemic vaccines, but only if they are coupled with improvements in the human infrastructure necessary for pandemic vaccination...

Meeting the challenge of influenza pandemic preparedness in developing countries

David S FedsonEmerg Infect Dis 15:365-71. 2009

..Without this research, industrialized and developing countries could face an unprecedented health crisis...

Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work

David S FedsonInfluenza Other Respir Viruses 3:129-42. 2009

..Research is urgently needed to determine whether these and other agents that modify the host response might be useful in managing H5N1 influenza and the next pandemic...

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe

Pandemic influenza: a potential role for statins in treatment and prophylaxis

David S FedsonClin Infect Dis 43:199-205. 2006

..Generic statins will be widely distributed and inexpensive. They might be the only agents that could alter the course of a global pandemic...

Preparing for pandemic vaccination: an international policy agenda for vaccine development

David S FedsonJ Public Health Policy 26:4-29. 2005

..Whether this international policy agenda for pandemic vaccine development will succeed is uncertain, but it will provide a good indication of whether "good governance" for global public health can be achieved...

Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence

David S FedsonLancet Infect Dis 3:272-3; discussion 273-4. 2003

Pandemic influenza and the global vaccine supply

David S FedsonClin Infect Dis 36:1552-61. 2003

....

Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults

..However, because most influenza vaccine (85%) is produced in only eight countries, adequate production and equitable distribution of vaccine throughout the world will pose a serious challenge when the next influenza pandemic appears...

Interview with David S. Fedson, MD, Former Professor of Medicine, University of Virginia School of Medicine, and Director of Medical Affairs, Aventis Pasteur MSD by Madeline Drexler